Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption hampers the synthesis of nucleotides required for DNA and RNA production, thereby limiting the proliferation of rapidly dividing cells such as immune cells and cancer cells.

The specific dose of Methotrexat Accord is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and treatment goals. Dosage regimens vary widely across the different approved indications.

Methotrexat Accord is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexat Accord shares the antifolate mechanism with drugs such as pemetrexed and leflunomide, but methotrexate has a broader range of approved indications, including both inflammatory diseases and several cancers. Its safety profile and dosing flexibility differ, making it a preferred choice in many rheumatologic and oncologic protocols.

Methotrexat Accord should be stored at room temperature, below 25 °C, in its original container. The packaging protects the product from moisture and light, helping maintain stability until the point of use.

The product is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular or intrathecal routes, depending on the therapeutic indication and clinical protocol. Administration is performed by qualified healthcare professionals under aseptic conditions.

Serious risks include bone marrow suppression leading to severe cytopenias, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary fibrosis, renal failure, and rare anaphylactic reactions. Patients should be monitored regularly for these complications throughout treatment.

Methotrexat Accord is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or any component of the formulation, and patients with severe hepatic or renal impairment. Caution is also advised for those with pre‑existing lung disease or active infections.